Patent 11395848 was granted and assigned to Oramed (company) on July, 2022 by the United States Patent and Trademark Office.
Described herein are methods and compositions for treating diabetes mellitus, concerning oral pharmaceutical compositions comprising insulin in combination with a GLP-1 analogue.